Abstract:Previous studies regarding the association of p53 codon 72 Arg/Pro polymorphism with hepatocellular carcinoma (HCC) risk have provided conflicting and inconclusive findings. Thus, a meta-analysis of all currently available publications was performed to address this issue. Eleven individual case–control studies involving a total of 2,718 cases and 3,752 controls were identified after a systematic search of the PubMed, Embase, Web of Science, and Wanfang databases. The strength of the association of p53 codon 72 Arg/Pro polymorphism with HCC risk was estimated by the pooled odds ratio (OR) with its corresponding 95 % confidence interval (95 % CI). Subgroup analyses stratified by ethnicity, source of controls, gender, hepatitis virus infection status, and family history of HCC were also conducted to assess the association. Overall, significantly increased risk of HCC was identified among carriers of the homozygous genotype ProPro (OR ProPro vs. ArgArg = 1.38 (95 % CI, 1.03–1.85), P OR = 0.033; OR ProPro vs. ArgArg + ArgPro = 1.28 (95 % CI, 1.03–1.59), P OR = 0.026). In subgroup analysis by ethnicity, the pooled results suggested that the p53 codon 72 Arg/Pro polymorphism was associated with an increased risk of HCC in Asians and Caucasians (for Asians, OR ProPro vs. ArgArg + ArgPro = 1.17 (95 % CI, 1.02–1.34), P OR = 0.025; for Caucasians, OR ProPro vs. ArgArg = 1.65 (95 % CI, 1.07–2.56), P OR = 0.025; OR ProPro vs. ArgArg + ArgPro = 1.74 (95 % CI, 1.14–2.66), P OR = 0.010). Subgroup analyses by source of controls and hepatitis virus infection status further demonstrated the significant association, whereas stratification factors involving gender and family history of HCC did not modify the association between p53 codon 72 Arg/Pro polymorphism and HCC risk. This meta-analysis suggests that the p53 codon 72 Arg/Pro polymorphism may play a critical role in the development of HCC, and gender and family history of HCC may not modulate the effect of p53 codon 72 Arg/Pro in HCC risk.

P53 Arg72Pro Polymorphism and the Risk of Glioma: a Meta-Analysis

P53 Codon 72 Polymorphism And Hematological Cancer Risk: An Update Meta-Analysis

Effect of CDKN2A/B rs4977756 polymorphism on glioma risk: a meta-analysis of 16 studies including 24077 participants

p53 Codon 72 polymorphism is associated with occurrence of cervical carcinoma in the Chinese population.

Arg72pro Polymorphism of Tp53 Gene and the Risk of Skin Cancer: A Meta-Analysis

Increased Risk of Cutaneous Melanoma Associated with P53 Arg72Pro Polymorphism

P53 Codon 72 Polymorphism and Gastric Cancer: A Meta-Analysis of the Literature

Association of P53 Arg72pro and Mdm2 Snp309 Polymorphisms with Glioma

Association between the p53 codon 72 Arg/Pro polymorphism and hepatocellular carcinoma risk

P53 Codon 72 Polymorphism and Ovarian Cancer Risk: a Meta-Analysis

P53 Polymorphism and Lung Cancer Susceptibility: a Pooled Analysis of 32 Case–control Studies

Association of TP53 Codon 72 Polymorphism with Cervical Cancer Risk in Chinese Women

Quantitative Assessment of the Association Between TP53 Arg72Pro Polymorphism and Bladder Cancer Risk.

P53 Codon 72 Polymorphism and Liver Cancer Susceptibility: A Meta-Analysis of Epidemiologic Studies

Associations Between P53 Arg72Pro and Development of Digestive Tract Cancers: A Meta-analysis

P53 Codon 72 Polymorphism and Gastric Cancer Risk in A Chinese Han Population

Homozygosity for Pro of P53 Arg72Pro As a Potential Risk Factor for Hepatocellular Carcinoma in Chinese Population

Association Between P53 Arg72Pro Polymorphism and the Risk of Human Papillomavirus-related Head and Neck Squamous Cell Carcinoma: A Meta-analysis

Interaction of P53 Arg72Pro and MDM2 T309G Polymorphisms and Their Associations with Risk of Gastric Cardia Cancer.

The Association Between TP53 Arg72pro Polymorphism and Non-Melanoma Skin Cancer Risk: A Meta-Analysis Including 7,107 Subjects

Correlation Between ERCC2 K751Q Polymorphisms and the Risk of Glioma: a Mata-Analysis